|Bid||312.71 x 800|
|Ask||313.01 x 1000|
|Day's range||304.44 - 313.42|
|52-week range||261.61 - 372.61|
|Beta (3Y monthly)||1.34|
|PE ratio (TTM)||54.72|
|Earnings date||29 Jul 2019 - 2 Aug 2019|
|Forward dividend & yield||N/A (N/A)|
|1y target est||343.08|
Illumina, Inc. today announced that it has filed another patent infringement suit against one of BGI Group’s subsidiaries, BGI Europe A/S. Illumina filed suit in the Maritime & Commercial High Court of Denmark.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
Some testing firms are finding it works better when health-care providers are more directly involved. Helix, which launched in 2015 with $100 million from genome-sequencing giant Illumina Inc., had planned to sell tests directly through an “app store’’ for DNA. Instead, it’s now looking to partner with health-care providers.
Illumina, Inc. (ILMN) today announced that its executives will be speaking at the following investor conference and invited investors to participate via webcast. The live webcast can be accessed in the Investor Relations section of Illumina's web site under the "company" tab at www.illumina.com. A replay of the presentation will be posted on Illumina’s web site after the event and will be available for at least 30 days following.
Illumina's (ILMN) NextSeq and MiSeq placements witness year-over-year growth, with the strength of the former being driven by solid demand for TSO500.
The gene-sequencing leader's revenue and earnings growth rates slowed down in the first quarter, but stronger growth is likely on the way.
On a per-share basis, the San Diego-based company said it had net income of $1.57. Earnings, adjusted for non-recurring costs, came to $1.60 per share. The results exceeded Wall Street expectations. The ...
Investing.com - Illumina (NASDAQ:ILMN) reported first quarter earnings that Beat analysts' expectations on Thursday and revenue that topped forecasts.
The global demand for healthcare products and services will keep growing significantly. Here's your complete guide to finding the best healthcare stocks and ETFs.
The global medical device space takes significant strides in terms of research and development (R&D) and regulatory progress in the first quarter.
The gene-sequencing pioneer isn't likely to hit a home run in Q1. But Illumina should run up the score later in 2019.